The Haptoglobin 2-2 group randomised to Vitamin E

The Haptoglobin 2-2 group randomised to placebo

The Non Haptoglobin 2-2 group randomised to Vitamin E

The Non Haptoglobin 2-2 group randomised to placebo

Diabetes Mellitus

Two hundred patients will be recruited to a pilot randomized controlled trial (RCT), stratified by Hp 2-2 phenotype status (100 Hp 2-2 and 100 non-Hp 2-2), and randomly allocated in a 1:1 ratio to either vitamin E 400 IU supplementation daily for 6 months or a placebo group. The trial will determine whether vitamin E improves the aforementioned surrogate markers in the Hp phenotype strata.

Vitamin E

Placebo

Tan Tock Seng Hospital

Relationship of Haptoglobin Phenotype to Vascular Function and Response to Vitamin E Supplementation in Patients With Diabetes Mellitus Type 2: The EVAS Trial

Measured as Reactive hyperemia index using RHI-EndoPAT

Measured as pulse wave velocity using the sphygmocor device

Measured as ratio between retinal arterial diameter and venous diameter as retinal AV index

Lee Kong Chian School of Medicine, Nanyang Technological University

National Medical Research Council (NMRC), Singapore

Diabetes Type 2

Vitamin C

National Institutes of Health Clinical Center, 9000 Rockville Pike

Famine From Feast: Linking Vitamin C, Red Blood Cell Fragility, and Diabetes

changes in RBC vitamin C levels in diabetics in relation to acute glycemic control

effect of vitamin C supplementation on RBC deformability

alpha tocopherol/hypoxia

Relationship of Haptoglobin Phenotype to Vascular Function and Response to Vitamin E Supplementation in Patients With Diabetes Mellitus Type 2: The EVAS Trial

Famine From Feast: Linking Vitamin C, Red Blood Cell Fragility, and Diabetes

Baza e të dhënave më e plotë e bimëve medicinale e mbështetur nga shkenca